Full Text
Budget impact analysis of utilizing canagliflozin (CANA) for the treatment of type 2 diabetes mellitus (T2DM) in an United States health plan

Abstract

Authors

L. Vo S. Martin

Back to Volume 17, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×